| Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results NCT01179048 | Completed | P3 | Novo Nordisk A/S |
| A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes NCT01794143 | Completed | P3 | GRADE Study Group |
| Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes NCT02730377 | Completed | P4 | Novo Nordisk A/S |
| Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes NCT01336023 | Completed | P3 | Novo Nordisk A/S |
| To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together NCT00318461 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00318422 | Completed | P3 | Novo Nordisk A/S |
| A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus NCT02501161 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes NCT00856986 | Completed | P3 | Novo Nordisk A/S |
| Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure NCT01117350 | Completed | P4 | Sanofi |
| Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00614120 | Completed | P3 | Novo Nordisk A/S |
| Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes NCT01029886 | Completed | P3 | AstraZeneca |
| A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. NCT01128894 | Completed | P3 | GlaxoSmithKline |
| A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes NCT03235050 | Completed | P2 | AstraZeneca |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. NCT02607306 | Completed | P3 | Novo Nordisk A/S |
| Prognostic Predictors of Response to Hypoglycemic Therapy NCT03804411 | Unknown | P4 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health |
| To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c NCT00294723 | Terminated | P3 | Novo Nordisk A/S |
| A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) NCT03172494 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus NCT00700817 | Completed | P3 | Novo Nordisk A/S |
| Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) NCT01296412 | Completed | P3 | Merck Sharp & Dohme LLC |
| A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. NCT02505334 | Completed | P3 | Novo Nordisk A/S |
| A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes NCT01624259 | Completed | P3 | Eli Lilly and Company |
| Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM NCT01658501 | Completed | P2 | PhaseBio Pharmaceuticals Inc. |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00331851 | Completed | P3 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00333151 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus NCT01952145 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period NCT02787551 | Completed | P3 | Sanofi |
| A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Unknown | P3 | Tonghua Dongbao Pharmaceutical Co.,Ltd |
| A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus NCT02420262 | Completed | P3 | Novo Nordisk A/S |
| A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) NCT01733758 | Completed | P3 | GlaxoSmithKline |
| A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus NCT01558271 | Completed | P3 | Eli Lilly and Company |
| Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00518882 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) NCT03175120 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes NCT01617434 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy NCT01676116 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy NCT01618162 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | Recruiting | P4 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes NCT04373967 | Unknown | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms NCT02298192 | Completed | P3 | Novo Nordisk A/S |
| A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus NCT02773368 | Completed | P3 | Novo Nordisk A/S |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes NCT01392573 | Completed | P3 | Novo Nordisk A/S |
| Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin NCT01388361 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin NCT01907854 | Completed | P4 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes NCT01973231 | Completed | P4 | Novo Nordisk A/S |
| Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00393718 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes NCT02008682 | Completed | P4 | Novo Nordisk A/S |
| Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone NCT01512108 | Completed | P3 | Novo Nordisk A/S |
| The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification NCT01664247 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes NCT01917656 | Completed | P4 | Novo Nordisk A/S |
| LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. NCT02964247 | Completed | P3 | Novo Nordisk A/S |
| Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes NCT03421119 | Unknown | P3 | Cinnagen |
| A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus NCT02973321 | Completed | P2 | Sanofi |
| Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment NCT01620489 | Completed | P3 | Novo Nordisk A/S |
| Liraglutide Hospital Discharge Trial NCT01919489 | Completed | P4 | Emory University |
| RISE Adult Medication Study NCT01779362 | Completed | P3 | RISE Study Group |
| Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00395746 | Completed | P3 | Novo Nordisk A/S |
| Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) NCT04196231 | Completed | P4 | University of Campania Luigi Vanvitelli |
| Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes NCT01572740 | Completed | P3 | Novo Nordisk A/S |
| The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes NCT06408532 | Unknown | P4 | Peking University People's Hospital |
| Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes NCT02057172 | Completed | P2 | Hanmi Pharmaceutical Company Limited |
| Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes NCT00154414 | Completed | P2 | Novo Nordisk A/S |